These methods include intertumoral injection of TLR ligands, introducing TNF ligand superfamily member 14 (LIGHT), injecting oncolytic viruses, and delivering type I IFN directly into the tumor microenvironment using tumor-targeting mAbs conjugated to IFN-β (137). Here, TNFSF14 is linked to neoplasm.